GelMEDIX is developing therapies that restore vision loss by regenerating damaged retinal cells and preserving the essential structures required for sight.

 

Our groundbreaking biomaterials technology has unlocked a new approach to optimize the delivery, efficacy, and safety of cell and gene therapies. GelMEDIX programs are based on our proprietary injectable hydrogel scaffold technology that we have engineered improve the functional replacement and integration of therapeutic cells and the delivery of gene therapies.

 

Our team combines deep expertise in biomaterials engineering, regenerative medicine, and ophthalmology with this technology platform to develop vision-restoring therapies that overcome the limitations of current cell therapy approaches. We believe our approach opens a new frontier for the development of treatments with the potential to restore vision in patients who currently have limited or no options.

 

Our lead program, GMX-101, is a retinal pigment epithelial (RPE) cell therapy engineered to restore vision and stop disease progression in patients with late-stage Geographic Atrophy (GA), a leading cause of irreversible blindness in adults over 60.

 

We aim to optimize the potential of our regenerative medicine platform by building a pipeline of next-generation therapies for degenerative eye diseases and by forging partnerships to optimize cell and gene therapies for other degenerative disorders. 

 

Join us on this exciting journey toward restoring sight!

​